<DOC>
	<DOCNO>NCT01188928</DOCNO>
	<brief_summary>The purpose study compare efficacy safety Calcipotriol 50 Mcg/g Plus Betamethasone 0.5 mg/g ( Dipropionate ) Topical Suspension active component use individually monotherapy topical suspension vehicle ( betamethasone dipropionate topical suspension vehicle , calcipotriol topical suspension vehicle ) topical suspension vehicle alone treatment psoriasis vulgaris non-scalp region body ( trunk and/or limb ) large phase 3 study . This comparison ensure inform assessment benefit/risk ratio Calcipotriol 50 Mcg/g Plus Betamethasone 0.5 mg/g ( Dipropionate ) Topical Suspension also establish optimal treatment duration psoriasis vulgaris non-scalp region body ( trunk and/or limb ) .</brief_summary>
	<brief_title>LEO 80185 Treatment Psoriasis Vulgaris Non-scalp Regions Body ( Trunk and/or Limbs )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Signed date informed consent obtain prior trial related activity ( include washout period ) . Aged 18 year Either sex Any race ethnicity Attending hospital outpatient clinic private practice board certify dermatologist . Clinical diagnosis stable plaque psoriasis vulgaris least 6 month duration involve nonscalp region body ( trunk and/or limb ) amenable treatment maximum 100 g topical medication per week . An investigator 's global assessment disease severity ( IGA ) mild moderate body ( trunk and/or limb ) Day 0 ( Visit 1 ) . A minimum modified Psoriasis Area Severity Index ( PASI ) score extent 2 least one body region ( i.e . psoriasis affect least 10 % arm , and/or 10 % trunk , and/or 10 % leg ) Females childbearing potential must negative pregnancy test Day 0 ( Visit 1 ) . Females childbearing potential must agree use highly effective method birth control study . A highly effective method birth control define one result low failure rate ( le 1 % per year ) implant , injectables , combine oral contraceptive , intrauterine device , sexual abstinence vasectomise partner . The patient must use contraceptive method continually least 1 month prior pregnancy test , must continue use contraceptive method least 1 week last application study medication . A female defined childbearing potential postmenopausal ( 12 month menses without alternative medical cause ) , surgically sterile ( tubal ligation/section , hysterectomy bilateral ovariectomy ) . Able communicate investigator understand comply requirement study . Systemic treatment biological therapy , whether market , possible effect psoriasis vulgaris within follow time period prior randomisation : etanercept within 4 week prior randomisation adalimumab , alefacept , infliximab within 2 month prior randomisation ustekinumab within 4 month prior randomisation experimental product within 4 weeks/5 halflives ( whichever longer ) prior randomisation Systemic treatment therapy possible effect psoriasis vulgaris ( e.g. , corticosteroid , retinoids , methotrexate , cyclosporine immunosuppressant ) within 4 week prior randomisation . PUVA Grenz ray therapy within 4 week prior randomisation . UVB therapy within 2 week prior randomisation . Any topical treatment trunk and/or limb ( except emollient ) within 2 week prior randomisation . Topical treatment relevant skin disorder face flexure ( e.g. , facial flexural psoriasis , eczema ) class 1 5 corticosteroid vitamin D analogue within 2 week prior randomisation . Topical treatment relevant skin disorder scalp ( e.g . scalp psoriasis ) class 15 corticosteroid , vitamin D analogue prescription shampoo within 2 week prior randomisation . Planned initiation , change , concomitant medication could affect psoriasis vulgaris ( e.g . beta blocker , antimalarial , lithium , ACE inhibitor ) study . Current diagnosis guttate , erythrodermic , exfoliative pustular psoriasis . Subjects follow condition present treatment area : viral ( e.g . herpes varicella ) lesion skin , fungal bacterial skin infection , parasitic infection , skin manifestation relation syphilis tuberculosis , rosacea , perioral dermatitis , acne vulgaris , atrophic skin , stria atrophicae , fragility skin vein , icthyosis , acne rosacea , ulcer wound . Known suspect disorder calcium metabolism associate hypercalcaemia . Known suspect severe renal insufficiency severe hepatic disorder . Known suspect hypersensitivity component ( ) investigational product . Current participation interventional clinical study . Subjects receive treatment nonmarketed drug substance ( i.e . agent yet make available clinical use follow registration ) within 4week period prior randomisation longer , class substance require longer washout define ( e.g . biological treatment ) . Planned excessive exposure sun study may affect psoriasis vulgaris . Previously randomise study . Females pregnant , positive pregnancy test Day 0 ( Visit 1 ) , breastfeed . Females childbearing potential wishing become pregnant study , use adequate method contraception study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>